Literature DB >> 8763844

Tertiary amine N-oxides as bioreductive drugs: DACA N-oxide, nitracrine N-oxide and AQ4N.

W R Wilson1, W A Denny, S M Pullen, K M Thompson, A E Li, L H Patterson, H H Lee.   

Abstract

Tertiary amine N-oxides of DNA intercalators with alkylamino sidechains are a new class of bioreductive drugs. N-oxidation masks the cationic charge of the amines, forming prodrugs with low DNA binding affinity and low toxicity which can be activated selectively by metabolic reduction under hypoxic conditions. This study compares three intercalator N-oxides (NC-NO, DACA-NO and AQ4N), which, respectively, give nitracrine (NC), DACA and AQ4 on reduction. In aerobic cell culture all three N-oxide were much less toxic than the corresponding amines, and showed large increases in cytotoxicity under hypoxia. The topoisomerase poisons DACA and AQ4 (and their N-oxides) were less active against non-cycling than cycling cells. However, only AQ4N was active against the mouse mammary tumour MDAH-MCa-4. This dialkylaminoanthraquinone-di-N-oxide has activity at least as great as the reference bioreductive drug RB 6145 against this tumour, both with and without radiation and when combined with the tumour blood flow inhibitor 5,6-dimethylxanthenone-4-acetic acid (DMXAA). It is suggested that the high in vivo activity of AQ4N relative to the other topoisomerase-targeted N-oxide, DACA-NO, may be in part due to release in hypoxic cells of an intracalator with sufficiently high DNA binding affinity that it is retained long enough to kill non-cycling cells when they eventually re-enter the cell cycle.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8763844      PMCID: PMC2149993     

Source DB:  PubMed          Journal:  Br J Cancer Suppl        ISSN: 0306-9443


  12 in total

1.  Considerations for the design of nitrophenyl mustards as agents with selective toxicity for hypoxic tumor cells.

Authors:  W A Denny; W R Wilson
Journal:  J Med Chem       Date:  1986-06       Impact factor: 7.446

2.  Selectivity of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide towards Lewis lung carcinoma and human tumour cell lines in vitro.

Authors:  G J Finlay; B C Baguley
Journal:  Eur J Cancer Clin Oncol       Date:  1989-02

3.  Reductive chemistry of the novel hypoxia-selective cytotoxin 5-[N,N-bis(2-chloroethyl)amino]-2,4-dinitrobenzamide.

Authors:  B D Palmer; P van Zijl; W A Denny; W R Wilson
Journal:  J Med Chem       Date:  1995-03-31       Impact factor: 7.446

4.  Bis-bioreductive agents as hypoxia-selective cytotoxins: nitracrine N-oxide.

Authors:  W R Wilson; P Van Zijl; W A Denny
Journal:  Int J Radiat Oncol Biol Phys       Date:  1992       Impact factor: 7.038

5.  Combining bioreductive drugs (SR 4233 or SN 23862) with the vasoactive agents flavone acetic acid or 5,6-dimethylxanthenone acetic acid.

Authors:  S Cliffe; M L Taylor; M Rutland; B C Baguley; R P Hill; W R Wilson
Journal:  Int J Radiat Oncol Biol Phys       Date:  1994-05-15       Impact factor: 7.038

6.  Potential antitumor agents. 50. In vivo solid-tumor activity of derivatives of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide.

Authors:  G J Atwell; G W Rewcastle; B C Baguley; W A Denny
Journal:  J Med Chem       Date:  1987-04       Impact factor: 7.446

7.  Hypersensitivity to cell killing and mutation induction by chemical carcinogens in an excision repair-deficient mutant of CHO cells.

Authors:  L H Thompson; E P Salazar; K W Brookman; C A Hoy
Journal:  Mutat Res       Date:  1983-12       Impact factor: 2.433

8.  N-[2-(2-methyl-5-nitroimidazolyl)ethyl]-4-(2-nitroimidazolyl)butanamide (NSC 639862), a bisnitroimidazole with enhanced selectivity as a bioreductive drug.

Authors:  J W Moselen; M P Hay; W A Denny; W R Wilson
Journal:  Cancer Res       Date:  1995-02-01       Impact factor: 12.701

Review 9.  Rationale for the use of aliphatic N-oxides of cytotoxic anthraquinones as prodrug DNA binding agents: a new class of bioreductive agent.

Authors:  L H Patterson
Journal:  Cancer Metastasis Rev       Date:  1993-06       Impact factor: 9.264

10.  Aliphatic amine N-oxides of DNA binding agents as bioreductive drugs.

Authors:  L H Patterson; M R Craven; G R Fisher; P Teesdale-Spittle
Journal:  Oncol Res       Date:  1994       Impact factor: 5.574

View more
  11 in total

Review 1.  Recent developments in the design of bioreductive drugs.

Authors:  W A Denny; W R Wilson; M P Hay
Journal:  Br J Cancer Suppl       Date:  1996-07

2.  Hypoxia signaling: Challenges and opportunities for cancer therapy.

Authors:  Mircea Ivan; Melissa L Fishel; Oana M Tudoran; Karen E Pollok; Xue Wu; Paul J Smith
Journal:  Semin Cancer Biol       Date:  2021-10-07       Impact factor: 15.707

3.  Impact of tumor blood flow modulation on tumor sensitivity to the bioreductive drug banoxantrone.

Authors:  Eugene Manley; David J Waxman
Journal:  J Pharmacol Exp Ther       Date:  2012-11-28       Impact factor: 4.030

4.  Enamine N-Oxides: Synthesis and Application to Hypoxia-Responsive Prodrugs and Imaging Agents.

Authors:  Dahye Kang; Sheldon T Cheung; Andrew Wong-Rolle; Justin Kim
Journal:  ACS Cent Sci       Date:  2021-03-29       Impact factor: 14.553

5.  An experimental and mathematical model for the extravascular transport of a DNA intercalator in tumours.

Authors:  K O Hicks; S J Ohms; P L van Zijl; W A Denny; P J Hunter; W R Wilson
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

6.  Enhancement of chemotherapy and radiotherapy of murine tumours by AQ4N, a bioreductively activated anti-tumour agent.

Authors:  L H Patterson; S R McKeown; K Ruparelia; J A Double; M C Bibby; S Cole; I J Stratford
Journal:  Br J Cancer       Date:  2000-06       Impact factor: 7.640

7.  Enhancement of the anti-tumour effects of the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) by combination with 5-hydroxytryptamine and bioreductive drugs.

Authors:  C J Lash; A E Li; M Rutland; B C Baguley; L J Zwi; W R Wilson
Journal:  Br J Cancer       Date:  1998-08       Impact factor: 7.640

8.  2-Amino metabolites are key mediators of CB 1954 and SN 23862 bystander effects in nitroreductase GDEPT.

Authors:  N A Helsby; D M Ferry; A V Patterson; S M Pullen; W R Wilson
Journal:  Br J Cancer       Date:  2004-03-08       Impact factor: 7.640

Review 9.  Prodrugs for amines.

Authors:  Ana L Simplício; John M Clancy; John F Gilmer
Journal:  Molecules       Date:  2008-03-03       Impact factor: 4.411

Review 10.  Metabolic N-Dealkylation and N-Oxidation as Elucidators of the Role of Alkylamino Moieties in Drugs Acting at Various Receptors.

Authors:  Babiker M Eh-Haj
Journal:  Molecules       Date:  2021-03-29       Impact factor: 4.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.